ASH 2023 | The value of MRD as a marker for disease eradication in AML
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the value of measurable residual disease (MRD) as a marker for disease eradication and a predictor of treatment outcomes in acute myeloid leukemia (AML). He mentions the QuANTUM-First trial (NCT02668653), which provides evidence for the value of FLT3-ITD-specific MRD in predicting treatment outcomes, as well as the BMT CTN 0901 study (NCT01339910). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Yeah, there are studies that are continuing to look at the value of measurable residual disease in the setting of AML therapy. There are data from QuANTUM-First that clearly demonstrate that the very sensitive FLT3-ITD molecular assay for MRD can be very important. And also study data also is being presented from the, BMT CTN study. I think MRD assessment is of high value in AML, and we need to continue to work towards developing better MRD markers and better and more sensitive MRD assays in AML, just like as we have seen in ALL, this can lead to, significant improvements...
Yeah, there are studies that are continuing to look at the value of measurable residual disease in the setting of AML therapy. There are data from QuANTUM-First that clearly demonstrate that the very sensitive FLT3-ITD molecular assay for MRD can be very important. And also study data also is being presented from the, BMT CTN study. I think MRD assessment is of high value in AML, and we need to continue to work towards developing better MRD markers and better and more sensitive MRD assays in AML, just like as we have seen in ALL, this can lead to, significant improvements. And also MRD eradication is important. We also have a study of XmAb14045, which is also being presented as an oral abstract looking at this agent, which is a bispecific antibody in eradicating MRD in AML. And hopefully we will have better agents in the future to try to eradicate MRD.
Read more...
Disclosures
Prelude: Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Syros: Consultancy, Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; Xencor: Research Funding; Biomea fusion: Honoraria, Research Funding; Celgene/BMS: Consultancy, Honoraria, Research Funding; Astex/taiho: Membership on an entity’s Board of Directors or advisory committees, Research Funding.
